Abbott Park, Illinois (ots-PRNewswire) - Abbott Laboratories
(NYSE: ABT) today announced that it has entered into an agreement
with Enfer Scientific Ltd. for the marketing and distribution of two
diagnostic tests used to detect bovine spongiform encephalopathy
(BSE) in cattle.
The tests, developed by Enfer Scientific, an animal diagnostics
company in Tipperary, Ireland, are used to detect the presence of the
abnormal prion protein associated with BSE, also known as "mad cow
disease." The first is a four-hour ELISA (enzyme-linked
immunosorbent assay) test, approved by the European Commission. The
features of the test, including its rapid turnaround time and high
throughput capabilities, make it ideally suited for testing for mad
The second test is a supplemental diagnostic test used to confirm
positive results. Both tests are conducted on brain tissue and
spinal cord samples from cattle.
"Abbott's leadership position in diagnostics and its global
presence will ensure that these important products are made widely
available to meet a growing demand for reliable and sensitive BSE
tests," said Thomas D. Brown, senior vice president, diagnostic
operations, Abbott Laboratories.
The tests are manufactured by Enfer Scientific and will be
marketed by Abbott under the Enfer name.
"We believe we have two very effective tests that improve the
speed and reliability of BSE testing," said Louis Ronan, director of
Enfer Scientific. "By helping to ensure that only BSE-free meat
enters the human food chain, these tests are making an important
contribution to public safety."
BSE is a transmissible, neuro-degenerative brain disease of
cattle. BSE first came to the attention of the scientific community
in November 1986 with the appearance in cattle of a newly recognised
form of neurological disease in the United Kingdom. The prevailing
theory is that the disease crossed the species barrier from cows to
humans, and that people may catch the disease from eating beef that
contains prion proteins. Prion proteins are a normal component of
human and animal brains, but if they assume the wrong shape, they
become lethal as they create plaques that are toxic to brain tissue.
Abbott Laboratories is a global, diversified health care company
devoted to the discovery, development, manufacture and marketing of
pharmaceutical, diagnostic, nutritional and hospital products. The
company employs approximately 70,000 people and markets its products
in more than 130 countries. In 2000, the company's sales and net
earnings were US $13.7 billion and $2.8 billion, respectively, with
diluted earnings per share of $1.78.
ots Original Text Service: Abbot Laboratories
Media: Don Braakmann,
or Financial: John Thomas,
both of Abbott Laboratories
Web site: http://www.abbott.com
Original-Content von: Abbott Laboratories, übermittelt durch news aktuell